Your Meds Aren't Working Because Your Genes Metabolize Them Too Fast.

CYP2D6 is your liver’s workhorse enzyme. It’s responsible for metabolizing roughly 25% of all medications in clinical use, including antidepressants, opioids, beta-blockers, and pain medications. If your metabolism of these drugs is working smoothly, you get therapeutic benefit. If it’s not, you get nothing.

Variants in CYP2D6 come in several types. The most common poor-metabolizer variants are called *2, *4, *10, and *17. If you carry two copies of a poor-metabolizer variant, you’re a poor metabolizer, meaning your CYP2D6 enzyme works at reduced capacity. Some people have gene duplications, meaning they have extra copies of CYP2D6, making them ultra-rapid metabolizers. Roughly 7-10% of people with European ancestry are poor metabolizers, while ultra-rapid metabolizers are less common but clinically important.

If you’re an ultra-rapid metabolizer, medications like antidepressants and pain relievers get broken down so fast they never build up to therapeutic levels in your blood. You take the medication and feel nothing. If you’re a poor metabolizer, the opposite happens: medications accumulate to toxic levels, causing side effects at standard doses. You might feel dizzy, nauseated, or sedated on a dose that should be safe.

CYP2C19 metabolizes clopidogrel (Plavix), a critical blood-thinning medication prescribed after heart attacks and stent placement. It also metabolizes many antidepressants and proton pump inhibitors for acid reflux. The stakes with this gene are high: if your variant prevents proper metabolism, you don’t get the antiplatelet benefit when you need it most.

Common poor-metabolizer variants are *2 and *3. Rapid-metabolizer variants include *17. Poor metabolizers make up roughly 2-15% of the population depending on ancestry. Here’s the critical detail: clopidogrel is a prodrug, meaning it requires CYP2C19 to convert it into its active form. If you’re a poor CYP2C19 metabolizer, clopidogrel stays inactive in your bloodstream, leaving you at risk of stent thrombosis or recurrent heart attack despite taking the medication. Ultra-rapid metabolizers, by contrast, activate it too quickly and face elevated bleeding risk.

For antidepressants metabolized by CYP2C19, poor metabolizers accumulate higher blood levels and experience side effects at standard doses. Ultra-rapid metabolizers get no therapeutic effect. The symptom feels the same either way: the medication doesn’t help, or it causes unbearable side effects.

CYP2C9 metabolizes warfarin, the gold-standard blood thinner for atrial fibrillation and clotting disorders. It also processes NSAIDs like ibuprofen and naproxen, and statins used for cholesterol management. Variants in this gene have direct, measurable consequences for bleeding risk and therapeutic effectiveness.

The two most common poor-metabolizer variants are *2 and *3, present in roughly 5-10% of people with European ancestry. Poor metabolizers cannot efficiently clear warfarin, causing it to accumulate to dangerous levels in their blood even at standard doses. This doesn’t mean warfarin is contraindicated; it means the dose must be substantially lower, sometimes half the standard dose. Taking a standard warfarin dose with a CYP2C9 poor-metabolizer variant puts you at serious risk of bleeding.

With NSAIDs, poor metabolizers experience prolonged drug exposure and elevated risk of gastrointestinal bleeding and ulcers. With statins, the same accumulation effect increases muscle pain and damage. Your doctor has no way of knowing without testing your CYP2C9 variant status.

VKORC1 encodes vitamin K epoxide reductase, the enzyme that recycles vitamin K in your body. Warfarin works by blocking this enzyme, preventing blood clotting. But the sensitivity of your VKORC1 enzyme to warfarin’s blocking effect varies based on your genetics. This gene doesn’t metabolize warfarin; it determines how much warfarin you need to achieve therapeutic anticoagulation.

The most common variant is -1639G>A. The A allele is carried by roughly 40% of people with European ancestry. If you carry the A allele, your VKORC1 enzyme is inherently less efficient at recycling vitamin K, meaning you require significantly lower warfarin doses to achieve the same anticoagulant effect as someone without the variant. Standard warfarin dosing, which assumes normal VKORC1 function, can cause over-anticoagulation and bleeding in people with this variant.

You might experience unusual bruising, nosebleeds, or gum bleeding on a warfarin dose that should be safe. Your INR climbs higher than expected. Your doctor increases your vitamin K intake or decreases your warfarin dose, trying to find a stable range, not realizing the issue is your genetic sensitivity.

SLCO1B1 encodes a transporter protein that actively pumps statin molecules into liver cells. This step is essential: statins must reach high concentrations inside liver cells to lower cholesterol effectively. But genetic variants in SLCO1B1 reduce this transporter’s efficiency, meaning statins don’t make it into the liver in normal quantities. Instead, they accumulate in your bloodstream and muscle tissue.

The *5 variant, identified by the SNP rs4149056, is present in roughly 15% of the population. People carrying the *5 variant have a significant reduction in hepatic statin uptake. With reduced transporter function, the same statin dose results in higher systemic exposure, elevating your risk of statin myopathy, muscle pain, and muscle breakdown. You might experience unexplained muscle aches, weakness, or fatigue on a dose that should be safe for the general population.

You take a statin for cholesterol management, but instead of the benefit, you get muscle pain. Blood tests show muscle enzymes elevated. Your doctor lowers the dose or switches statins, but the problem persists if the underlying issue is SLCO1B1-related accumulation. You blame the medication or your body, when the real issue is reduced hepatic uptake.

MTHFR catalyzes a critical step in the methylation cycle, converting folate into its active form, methylfolate. This process supports not just energy production, but also the metabolism of certain medications. Drugs like methotrexate, trimethoprim, and phenytoin depend on adequate folate metabolism to work effectively and safely. When MTHFR function is compromised, both the drug’s effectiveness and your body’s ability to tolerate it are affected.

The most common MTHFR variant is C677T, present in roughly 40% of people with European ancestry. The C677T variant reduces MTHFR enzyme activity by 35-40%, impairing the folate-dependent metabolic pathways that certain medications require. This doesn’t mean the medication won’t work at all; it means your body’s capacity to metabolize it efficiently is reduced, and you may experience suboptimal results or unexpected sensitivities.

If you’re taking methotrexate for autoimmune disease or cancer, an MTHFR variant means your liver has reduced capacity to process the drug efficiently. You might need adjusted dosing or more frequent monitoring. With trimethoprim antibiotics, reduced folate availability can contribute to side effects like peripheral neuropathy or increased infection risk. Your doctor has no way to predict this without knowing your MTHFR status.